Beyond Air (XAIR) shares declined approximately 23% over the past 30 days, falling from $7.49 on July 13 to $5.75 as of August 12, 2026. The stock posted a steeper loss of roughly 46-52% over the last quarter, reflecting persistent pressure from Nasdaq compliance concerns, a 1-for-20 reverse stock split, and ongoing cash burn.

QDEL tumbled approximately -25% intraday Friday, extending a sharp after-hours and premarket selloff triggered by the company's Q2 2026 earnings release after Thursday's close. Q2 results beat estimates — revenue of $630.9M surpassed consensus and adjusted EPS of $0.13 cleared the -$0.05 forecast — but the beat was overshadowed by a dramatic full-year guidance reset.

CVRX plunged -54.71% during Friday's regular session, falling from a $5.94 prior close to approximately $2.69, with the selloff already evident in after-hours trading Thursday evening. The primary catalyst was CVRx's Q2 2026 earnings release after Thursday's close, where the company slashed full-year revenue guidance to $58M–$60M from $63M–$67M, citing sales-force execution failures.

PODD plunged -19.51% during regular trading on Wednesday, reaching a new 52-week low after the company reported Q2 2026 earnings and slashed its forward revenue outlook. The selloff began in premarket (shares fell ~10% before the open) and accelerated through the regular session despite Q2 beats: adjusted EPS of $1.66 topped the $1.45 consensus and revenue rose +23.5% YoY to $801.7 million.

BRKR closed at $50.30, plunging -21.79% during the regular trading session following the release of Q2 2026 earnings. The primary catalyst was a revenue miss: Q2 revenue of $838.5M fell short of the $853.39M analyst consensus, and the company lowered its full-year FY2026 revenue guidance midpoint to $3.56B from $3.59B, also below Street estimates.

AHCO plunged -38.13% during Tuesday's regular session, closing at $6.70 after reporting Q2 2026 results that severely missed expectations across all key metrics. The primary catalyst was a disastrous Q2 earnings report: adjusted EPS of -$0.99 versus consensus of +$0.15, and revenue of $740.3M missing the $848.9M estimate.

AHCO shares plunged approximately -41.50% during regular trading after the company reported Q2 2026 results that missed consensus estimates across all key metrics. The company posted a GAAP loss of -$0.99 per share, dramatically below the analyst consensus of +$0.15 profit, driven largely by a $144.2 million non-cash goodwill impairment charge.

BRKR shares plunged -18.02% to $52.72 during regular trading after reporting Q2 2026 results before the open, erasing recent gains from a prior close of $64.31. The primary catalyst was a top-and-bottom-line miss: revenue of $838.5M fell -1.9% short of the $854.8M consensus, and full-year revenue guidance was cut to $3.56B at the midpoint from $3.59B.

SYK shares tumbled -7.74% in regular trading Friday, extending the after-hours selloff that began following Thursday's Q2 2026 earnings release after the close. The company beat Q2 estimates with adjusted EPS of $3.69 and revenue of $6.59B, but the narrow revenue beat disappointed investors given Stryker's premium valuation.

Adjusted earnings per share (EPS) came in at $3.69, surpassing the consensus estimate of $3.49 by $0.20 and reflecting a 17.9% increase from $3.13 in the same quarter last year. Revenue reached $6.59 billion, edging past analyst expectations of $6.58 billion and representing year-over-year growth of 9.4%.

BSX dropped -5.88% during premarket and early regular trading after reporting Q2 2026 results that beat estimates but included a sharp guidance cut. Q2 earnings topped consensus: adjusted EPS of $0.86 vs. $0.83 expected, and revenue of $5.44 billion vs. $5.36 billion, driven by 7.5% year-over-year sales growth.

Abbott reported Q2 2026 adjusted earnings per share of $1.31, exceeding the consensus estimate of $1.28. Revenue reached $12.59 billion, reflecting year-over-year growth driven by key segments.

ABT surged +12.46% during Thursday's regular session after reporting Q2 2026 earnings premarket that beat estimates across key metrics. Adjusted EPS of $1.31 topped the $1.28 consensus, while revenue of $12.59B exceeded the $12.52B forecast, reflecting +13% reported sales growth year-over-year.

PRCT fell -9.05% during Tuesday's regular trading session, dropping from Monday's $21.22 close to approximately $19.30, with an intraday low of $18.88 marking a new 52-week low. The sell-off extended a prolonged downtrend — the stock is now down roughly -63% over the past year — with no single new catalyst; rather, accumulated competitive and reimbursement headwinds continued to weigh on sentiment.

SYK dropped -5.61% during regular trading hours, falling from a prior close of $331.45 to approximately $312.84 as of late morning. Goldman Sachs lowered its price target on Stryker to $339 from $363 while maintaining a Neutral rating, with the note published early this morning at 7:32 AM EDT.

Glaukos Corporation (GKOS) surged approximately 33.9% over the last 30 days, climbing from $110.78 on June 2, 2026, to $148.34 on July 2, 2026, and reaching a new 52-week high. The rally was fueled by a combination of a landmark reimbursement milestone for Epioxa, a pipeline advancement with GLK-321, and sustained commercial momentum from iDose TR.

Boston Scientific (BSX) shares fell approximately 20.3% over the last 30 days, dropping from $56.81 on May 19, 2026, to $45.29 on June 18, 2026. The quarterly decline is even steeper at roughly 36%, with the stock sliding from $71.28 in mid-March amid a broader medtech sector selloff.

NovoCure shares are down approximately 16% in premarket trading on June 18, 2026, with the stock quoted near $14.95 against a prior regular-session close of $17.85. The primary catalyst is the announcement that the company's Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary endpoint of demonstrating a statistically significant improvement in overall survival.

Medtronic reported Q4 revenue of $9.807 billion, up 9.9% as reported and 6.6% organically, exceeding implied guidance by 90 basis points. Full-year fiscal 2026 revenue reached $36.364 billion, up 8.4% as reported and 5.8% organically, marking the highest annual revenue growth in 10 years.

Medtronic is set to report fourth-quarter and full fiscal year 2026 results on June 3, 2026. Analyst consensus estimates call for Q4 revenue near $9.62 billion and non-GAAP EPS of approximately $1.55.